The combined activation of K(Ca)3.1 and inhibition of K(v)11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

BACKGROUND: Platinum-based drugs such as Cisplatin are commonly employed for cancer treatment. Despite an initial therapeutic response, Cisplatin treatment often results in the development of chemoresistance. To identify novel approaches to overcome Cisplatin resistance, we tested Cisplatin in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillozzi, Serena, D'Amico, Massimo, Bartoli, Gianluca, Gasparoli, Luca, Petroni, Giulia, Crociani, Olivia, Marzo, Tiziano, Guerriero, Angela, Messori, Luigi, Severi, Mirko, Udisti, Roberto, Wulff, Heike, Chandy, K George, Becchetti, Andrea, Arcangeli, Annarosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785745/
https://www.ncbi.nlm.nih.gov/pubmed/29161243
http://dx.doi.org/10.1038/bjc.2017.392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785745/
https://www.ncbi.nlm.nih.gov/pubmed/29161243
http://dx.doi.org/10.1038/bjc.2017.392

Ejemplares similares